期刊文献+

羟苯磺酸钙联合奥美沙坦治疗糖尿病肾病伴蛋白尿疗效观察 被引量:1

Observation of the Efficacy of Calcium Dobesilate Combined with Olmesartan for the Treatment of Proteinuria in Diabetic Nephropathy
下载PDF
导出
摘要 【目的】探讨羟苯磺酸钙联合奥美沙坦治疗糖尿病肾病(DN )的蛋白尿临床效果。【方法】将2012年2月至2013年4月就诊于本院的DN伴蛋白尿患者70例,随机分为观察组(35例)和对照组(35例)。对照组采用奥美沙坦等降血糖、降血脂、降血压等常规治疗,观察组在对照组基础上添加羟苯磺酸钙治疗。对比两组治疗前及治疗12周后患者的24 h尿白蛋白排泄率(UAER)、单核细胞趋化蛋白-1(MCP-1)、尿α1-微球蛋白(α1-MG)水平。【结果】治疗12周后24hUAER观察组下降更为明显,差异具有统计学意义( P <0.05)。观察组治疗总有效率为88%,显著高于对照组的68%,差异具有统计学意义( P <0.05)。【结论】羟苯磺酸钙联合奥美沙坦治疗DN的蛋白尿有良好疗效,安全性好。 [Objective]To explore the clinical efficacy of calcium dobesilate combined with olmesartan for the treatment of proteinuria in diabetic nephropathy (DN) .[Methods]A total of 70 DN patients with proteinu-ria in our hospital from Feb .2012 to April 2013 were randomly divided into observation group ( n =35) and control group( n=35) .The control group received regular treatment including olmesartan and other hypogly-cemic hypotensive treatment .The observation group was additionally given calcium dobesilate based on the treatment of control group .The 24h-urinary albumin excretion rates(UAER) ,monocyte chemotactic protein-1 (MCP-1) and urinary α1-microglobulin(α1-MG) before and 12 weeks after treatment were compared between two groups .[Results] The 24h-UAER in observation group after 12 weeks of treatment was decreased more obviously ,and there was significant difference( P 〈0 .05) .The total effective rate of observation group was 88% ,which was markedly higher than that of control group(68% ) ,and there was significant difference( P〈0 .05) .[Conclusion]Calcium dobesilate combined with olmesartan for the treatment of proteinuria in DN has good efficacy and safety .
出处 《医学临床研究》 CAS 2014年第3期517-518,521,共3页 Journal of Clinical Research
关键词 糖尿病肾病 并发症 蛋白尿 药物疗法 羟苯磺酸钙 投药和剂量 Diabetic Nephropathies/CO Proteinuria/DT Calcium Dobesilate/AD
  • 相关文献

参考文献14

二级参考文献99

共引文献195

同被引文献13

  • 1蒲琳,陆志明,林肯,吴桐.中西医结合治疗糖尿病肾病36例体会[J].实用医院临床杂志,2010,7(4):128-129. 被引量:4
  • 2马威,宋宇,李坤,等.糖尿病肾病危险因素分析[J].微循环学杂志,2012,22(4):76.
  • 3Gross G, Azevedo M J, Silveiro SP, et al. Diabetic nephropathy:di- agno prevention, and treatment [ J ]. Diabetes Care, 2005,28 ( 1 ) : 164 - 176.
  • 4Zhang X. Therapeutic effects of calcium dobesilate on diabetic ne- phropathy mediated through reduction of expression of PAI- 1 [ J ]. Exp Ther Med ,2013,5 (1) :295 -299.
  • 5Gilbert RE, Cox A, Wu L L, et al. Expression of transforming growth factor betal and type 1V collagen in the renal tubulointerstitium in experimental diabetes effects of ACE inhibition[ J]. Diabetes 1998, 47(33 !414 -422.
  • 6Hebert LA. Optimizing ACE - inhibitor therapy for chronic kidney disease [ J ]. N Engl J Med,2006,345 ( 2 ) : 189 - 191.
  • 7Andersen S, Jacobsen P, Taruow L, et al. Time course of the anti- proteinuric and antihypertensive effect of losartan in diabetic ne- phropathy [ J ]. Nephrol Dial Transplant,2003,18 ( 2 ) : 293 - 297.
  • 8Sasaki M, Uehara S, Ohta H, et al. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice [ J ]. Life Sci ,2004,75 (7) :869 - 880.
  • 9Mifsud SA, Allen TJ, Bertram JF, et al. Podocyte foot process broad- ening in experimental diabetic nephropathy: amelioration with ren- nin - angiotensin blockade [ J ].Diabetologia, 2001,44 ( 7 ) : 878 - 882.
  • 10高美娟,刘明,李波,李明龙,卞丽香,于桂娜.羟苯磺酸钙对早期糖尿病肾病大鼠肾脏的保护作用[J].药学学报,2009,44(2):126-133. 被引量:21

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部